STOCK TITAN

QIAGEN N.V. to release results for Q3 2023 and hold webcast

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
QIAGEN N.V. plans to release Q3 2023 results
Positive
  • QIAGEN N.V. announces plans to release its Q3 2023 results on October 30
Negative
  • None.

Venlo, the Netherlands, Oct. 09, 2023 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced its plans to release results for the third quarter 2023.

Press release date / time: Monday, October 30, shortly after 21:05 Frankfurt time / 20:05 London time / 16:05 New York time. (For Europe: Due to the U.S. time switch, our Press release will be published one hour earlier than usual.)

Conference call date / time: Tuesday, October 31, at 14:00 Frankfurt time / 13:00 London time / 09:00 New York time. 
(For Europe: Due to the U.S. time switch, our conference call will be held one hour earlier than usual.)

Three options for joining the conference call

  1. Register for call back connection - Click here: Connect me

Service available 15 minutes before call start 

  1. Dial-in by phone

U.S.: +1 646 828 8193
UK: +44 (0)330 165 3656
GER: +49 (0)69 6610 2491
Conference ID: 4759185
To avoid waiting time, please join the event conference 5-10 minutes prior to the start time. 

  1. Access the audio webcast - Click here: Access Webcast

A conference call replay will be available by using the following link:
https://globalmeet.webcasts.com/starthere.jsp?ei=1615915&tp_key=4b10c5e9f2

Contact: IR@qiagen.com

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to
 Insight solutions that enable customers to gain valuable molecular insights from samples containing
 the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from
blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable
 insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN
provides solutions to more than 500,000 customers around the world in Molecular Diagnostics
(human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of June 30, 2023, QIAGEN employed more than 6,100 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.

source: QIAGEN N.V. 
category: Financial


QIAGEN N.V. plans to release its Q3 2023 results on October 30.

The press release will be published shortly after 21:05 Frankfurt time / 20:05 London time / 16:05 New York time.

The conference call will be held on October 31 at 14:00 Frankfurt time / 13:00 London time / 09:00 New York time.

You can join the conference call by registering for call back connection, dialing in by phone, or accessing the audio webcast. Details are provided in the press release.

Yes, a conference call replay will be available using the provided link in the press release.
Qiagen NV

NYSE:QGEN

QGEN Rankings

QGEN Latest News

QGEN Stock Data

Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
Health Technology, Medical Specialties, Manufacturing, Biological Product (except Diagnostic) Manufacturing
Netherlands
Venlo

About QGEN

qiagen is the leading global provider of sample to insight solutions to transform biological materials into valuable molecular insights. qiagen sample technologies isolate and process dna, rna and proteins from blood, tissue and other materials. assay technologies make these biomolecules visible and ready for analysis. bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. automation solutions tie these together in seamless and cost-effective molecular testing workflows. qiagen provides these workflows to more than 500,000 customers around the world in molecular diagnostics (human healthcare), applied testing (forensics, veterinary testing and food safety), pharma (pharmaceutical and biotechnology companies) and academia (life sciences research). as of june 30, 2015, qiagen employed approximately 4,400 people in over 35 locations worldwide. further information can be found at http://www.qiagen.com.